PHARMARESOURCES (SHANGHAI) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.23 CNY | -12.99% |
|
-5.28% | +1.20% |
| Apr. 24 | PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
| Apr. 23 | PharmaResources Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The firm trades with high earnings multiples: 26.84 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.20% | 540M | - | ||
| +29.77% | 49.46B | B- | ||
| +1.00% | 42.58B | B | ||
| +50.24% | 42.49B | A | ||
| -5.26% | 29.09B | C | ||
| +13.68% | 26.61B | B- | ||
| -22.99% | 18.64B | B | ||
| +8.22% | 13.16B | B+ | ||
| +32.41% | 12.55B | C+ | ||
| +24.01% | 12.1B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 301230 Stock
- Ratings PharmaResources (Shanghai) Co., Ltd.
